Symbols / CVS
CVS Chart
About
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Healthcare Plans | Market Cap | 96.68B |
| Enterprise Value | 163.89B | Income | 1.77B | Sales | 399.83B |
| Book/sh | 59.18 | Cash/sh | 8.33 | Dividend Yield | 3.59% |
| Payout | 191.37% | Employees | 219000 | IPO | — |
| P/E | 54.67 | Forward P/E | 9.29 | PEG | — |
| P/S | 0.24 | P/B | 1.28 | P/C | — |
| EV/EBITDA | 11.21 | EV/Sales | 0.41 | Quick Ratio | 0.57 |
| Current Ratio | 0.84 | Debt/Eq | 106.06 | LT Debt/Eq | — |
| EPS (ttm) | 1.39 | EPS next Y | 8.18 | EPS Growth | 76.60% |
| Revenue Growth | 8.40% | Earnings | 2026-04-29 | ROA | 2.47% |
| ROE | 2.29% | ROIC | — | Gross Margin | 13.29% |
| Oper. Margin | 1.57% | Profit Margin | 0.44% | Shs Outstand | 1.27B |
| Shs Float | 1.27B | Short Float | 1.62% | Short Ratio | 2.10 |
| Short Interest | — | 52W High | 85.15 | 52W Low | 58.35 |
| Beta | 0.50 | Avg Volume | 8.36M | Volume | 2.68M |
| Target Price | $96.50 | Recom | Buy | Prev Close | $74.18 |
| Price | $75.99 | Change | 2.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$96.50
Mean price target
2. Current target
$75.95
Latest analyst target
3. DCF / Fair value
$83.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$75.95
Low
$79.00
High
$138.00
Mean
$96.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | main | Argus Research | Buy → Buy | $90 |
| 2026-01-27 | main | B of A Securities | Buy → Buy | $95 |
| 2025-12-17 | main | JP Morgan | Overweight → Overweight | $101 |
| 2025-12-12 | main | Bernstein | Market Perform → Market Perform | $87 |
| 2025-12-10 | main | Truist Securities | Buy → Buy | $98 |
| 2025-12-10 | reit | Piper Sandler | Overweight → Overweight | $101 |
| 2025-12-10 | main | UBS | Buy → Buy | $97 |
| 2025-12-10 | main | Barclays | Overweight → Overweight | $93 |
| 2025-12-10 | main | Mizuho | Outperform → Outperform | $95 |
| 2025-12-10 | main | Morgan Stanley | Overweight → Overweight | $93 |
| 2025-12-10 | main | Baird | Outperform → Outperform | $92 |
| 2025-12-05 | main | Bernstein | Market Perform → Market Perform | $86 |
| 2025-11-13 | main | Wells Fargo | Overweight → Overweight | $102 |
| 2025-11-03 | main | TD Cowen | Buy → Buy | $100 |
| 2025-10-30 | main | Evercore ISI Group | Outperform → Outperform | $95 |
| 2025-10-30 | main | RBC Capital | Outperform → Outperform | $93 |
| 2025-10-30 | main | Cantor Fitzgerald | Overweight → Overweight | $95 |
| 2025-10-30 | reit | Truist Securities | Buy → Buy | $95 |
| 2025-10-24 | main | UBS | Buy → Buy | $96 |
| 2025-10-14 | main | Morgan Stanley | Overweight → Overweight | $89 |
News
RSS: Latest CVS news- CVS Health put volume heavy and directionally bearish - Yahoo Finance Wed, 25 Feb 2026 15
- CVS Employee Bonuses Surge After Beating 2025 Profit Target - Bloomberg.com Mon, 23 Feb 2026 19
- CVS Earnings Beat Estimates. The Stock Fell. - Barron's ue, 10 Feb 2026 08
- CVS tops quarterly estimates, reaffirms profit outlook as turnaround plan takes effect - CNBC ue, 10 Feb 2026 08
- Should You Buy CVS Health Stock Before Feb. 10? - The Motley Fool Sat, 07 Feb 2026 08
- Is CVS Stock The Best Of The Worst? - Forbes Wed, 28 Jan 2026 08
- Clover Health (CLOV) To Report Earnings Tomorrow: Here Is What To Expect - TradingView Wed, 25 Feb 2026 11
- Fresh Look At CVS Health (CVS) Valuation After Recent Stock Pullback And Restructuring Charges - simplywall.st Mon, 23 Feb 2026 06
- CVS slides as Medicare Advantage reimbursement outlook weighs on managed-care sentiment - Quiver Quantitative ue, 24 Feb 2026 17
- Louisiana reaches $45 million settlement with CVS Health, ending lawsuits - News From The States Fri, 20 Feb 2026 22
- CVS Stock Climbed 35% Last Year. Is It Still a Buy in 2026? - TIKR.com ue, 03 Feb 2026 08
- CVS Health Corporation (NYSE:CVS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat Mon, 23 Feb 2026 06
- Louisiana reaches $45M settlement with CVS Health, AG announces - WNTZ-TV FOX 48 Mon, 23 Feb 2026 23
- Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips - Investing.com ue, 10 Feb 2026 14
- Assessing CVS Health (NYSE:CVS) Valuation After Recent Share Pullback And Earnings Charges - Yahoo Finance ue, 24 Feb 2026 00
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1800 | 136872 | — | Stock Award(Grant) at price 76.04 per share. | AGUIRRE FERNANDO | Director | — | 2025-11-20 00:00:00 | D |
| 1 | 1652 | 125618 | — | Stock Award(Grant) at price 76.04 per share. | SANSONE GUY P | Director | — | 2025-11-20 00:00:00 | D |
| 2 | 1775 | 134971 | — | Stock Award(Grant) at price 76.04 per share. | BALSER JEFFREY R M.D., PH.D. | Director | — | 2025-11-20 00:00:00 | D |
| 3 | 1652 | 125618 | — | Stock Award(Grant) at price 76.04 per share. | SHULMAN DOUGLAS H | Director | — | 2025-11-20 00:00:00 | D |
| 4 | 1652 | 125618 | — | Stock Award(Grant) at price 76.04 per share. | NORWALK LESLIE V | Director | — | 2025-11-20 00:00:00 | D |
| 5 | 1775 | 134971 | — | Stock Award(Grant) at price 76.04 per share. | BROWN C DAVID II | Director | — | 2025-11-20 00:00:00 | D |
| 6 | 1652 | 125618 | — | Stock Award(Grant) at price 76.04 per share. | KIRBY JOHN SCOTT | Director | — | 2025-11-20 00:00:00 | D |
| 7 | 591 | 44940 | — | Stock Award(Grant) at price 76.04 per share. | FINUCANE ANNE A | Director | — | 2025-11-20 00:00:00 | D |
| 8 | 7500 | 532650 | — | Sale at price 71.02 per share. | FINUCANE ANNE A | Director | — | 2025-08-20 00:00:00 | I |
| 9 | 1570 | 100009 | — | Purchase at price 63.70 per share. | SANSONE GUY P | Director | — | 2025-06-05 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.00B | -174.75M | -214.86M | -2.16B |
| TaxRateForCalcs | 0.19 | 0.25 | 0.25 | 0.26 |
| NormalizedEBITDA | 15.10B | 14.39B | 19.05B | 20.68B |
| TotalUnusualItems | -5.24B | -688.00M | -856.00M | -8.34B |
| TotalUnusualItemsExcludingGoodwill | -5.24B | -688.00M | -856.00M | -8.34B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 1.77B | 4.61B | 8.34B | 4.31B |
| ReconciledDepreciation | 4.61B | 4.60B | 4.37B | 4.22B |
| ReconciledCostOfRevenue | 346.70B | 321.41B | 303.35B | 267.96B |
| EBITDA | 9.86B | 13.70B | 18.20B | 12.35B |
| EBIT | 5.25B | 9.11B | 13.83B | 8.12B |
| NetInterestIncome | -3.12B | -2.96B | -2.66B | -2.29B |
| InterestExpense | 3.12B | 2.96B | 2.66B | 2.29B |
| NormalizedIncome | 6.01B | 5.13B | 8.99B | 10.49B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 1.77B | 4.61B | 8.34B | 4.31B |
| TotalExpenses | 391.68B | 363.11B | 343.18B | 306.18B |
| TotalOperatingIncomeAsReported | 4.66B | 8.52B | 13.74B | 7.95B |
| DilutedAverageShares | 1.26B | 1.29B | 1.32B | 1.33B |
| BasicAverageShares | 1.26B | 1.28B | 1.31B | 1.32B |
| DilutedEPS | 3.66 | 6.47 | 3.26 | 5.95 |
| BasicEPS | 3.67 | 6.49 | 3.29 | 6.00 |
| DilutedNIAvailtoComStockholders | 1.77B | 4.61B | 8.34B | 4.31B |
| NetIncomeCommonStockholders | 1.77B | 4.61B | 8.34B | 4.31B |
| NetIncome | 1.77B | 4.61B | 8.34B | 4.31B |
| MinorityInterests | 40.00M | 28.00M | -24.00M | -16.00M |
| NetIncomeIncludingNoncontrollingInterests | 1.73B | 4.59B | 8.37B | 4.33B |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | ||
| NetIncomeContinuousOperations | 1.73B | 4.59B | 8.37B | 4.33B |
| TaxProvision | 408.00M | 1.56B | 2.81B | 1.51B |
| PretaxIncome | 2.14B | 6.15B | 11.17B | 5.84B |
| OtherIncomeExpense | -5.13B | -589.00M | -768.00M | -8.17B |
| OtherNonOperatingIncomeExpenses | 112.00M | 99.00M | 88.00M | 169.00M |
| SpecialIncomeCharges | -5.24B | -688.00M | -856.00M | -8.34B |
| GainOnSaleOfPPE | 0.00 | 0.00 | -349.00M | -2.53B |
| GainOnSaleOfBusiness | 483.00M | 0.00 | 0.00 | |
| OtherSpecialCharges | -491.00M | 5.80B | 452.00M | |
| ImpairmentOfCapitalAssets | 5.72B | 0.00 | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 1.18B | 507.00M | 0.00 |
| NetNonOperatingInterestIncomeExpense | -3.12B | -2.96B | -2.66B | -2.29B |
| InterestExpenseNonOperating | 3.12B | 2.96B | 2.66B | 2.29B |
| OperatingIncome | 10.38B | 9.70B | 14.60B | 16.29B |
| OperatingExpense | 44.98B | 41.71B | 39.83B | 38.21B |
| OtherOperatingExpenses | 44.98B | 41.71B | 39.83B | 38.21B |
| GrossProfit | 55.36B | 51.40B | 54.43B | 54.50B |
| CostOfRevenue | 346.70B | 321.41B | 303.35B | 267.96B |
| TotalRevenue | 402.07B | 372.81B | 357.78B | 322.47B |
| OperatingRevenue | 402.07B | 372.81B | 357.78B | 322.47B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 516.00M | 518.00M | 480.00M | 458.00M |
| OrdinarySharesNumber | 1.27B | 1.26B | 1.29B | 1.30B |
| ShareIssued | 1.79B | 1.78B | 1.77B | 1.76B |
| NetDebt | 56.12B | 57.68B | 53.41B | 39.31B |
| TotalDebt | 79.95B | 82.92B | 79.39B | 70.73B |
| TangibleBookValue | -35.77B | -43.03B | -44.05B | -31.48B |
| InvestedCapital | 139.78B | 141.83B | 138.07B | 123.72B |
| WorkingCapital | -13.98B | -15.96B | -11.33B | -3.79B |
| NetTangibleAssets | -35.77B | -43.03B | -44.05B | -31.48B |
| CapitalLeaseObligations | 15.38B | 16.65B | 17.77B | 18.48B |
| CommonStockEquity | 75.21B | 75.56B | 76.46B | 71.47B |
| TotalCapitalization | 135.72B | 136.09B | 135.10B | 121.94B |
| TotalEquityGrossMinorityInterest | 75.38B | 75.73B | 76.64B | 71.77B |
| MinorityInterest | 168.00M | 170.00M | 175.00M | 300.00M |
| StockholdersEquity | 75.21B | 75.56B | 76.46B | 71.47B |
| GainsLossesNotAffectingRetainedEarnings | 406.00M | -120.00M | -297.00M | -1.26B |
| OtherEquityAdjustments | 406.00M | -120.00M | -297.00M | -1.26B |
| TreasuryStock | 36.79B | 36.82B | 33.84B | 31.86B |
| RetainedEarnings | 61.20B | 62.84B | 61.60B | 56.40B |
| CapitalStock | 50.40B | 49.66B | 48.99B | 48.19B |
| CommonStock | 50.40B | 49.66B | 48.99B | 48.19B |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 178.16B | 177.49B | 173.09B | 156.51B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 89.46B | 92.88B | 93.90B | 87.08B |
| OtherNonCurrentLiabilities | 9.49B | 10.33B | 11.67B | 12.56B |
| EmployeeBenefits | 1.99B | 3.31B | 3.25B | 3.23B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.99B | 3.31B | 3.25B | 3.23B |
| NonCurrentDeferredLiabilities | 3.83B | 3.81B | 4.31B | 4.02B |
| NonCurrentDeferredTaxesLiabilities | 3.83B | 3.81B | 4.31B | 4.02B |
| LongTermDebtAndCapitalLeaseObligation | 74.14B | 75.43B | 74.67B | 67.28B |
| LongTermCapitalLeaseObligation | 13.64B | 14.90B | 16.03B | 16.80B |
| LongTermDebt | 60.50B | 60.53B | 58.64B | 50.48B |
| CurrentLiabilities | 88.69B | 84.61B | 79.19B | 69.42B |
| OtherCurrentLiabilities | 1.12B | 1.18B | 1.14B | 2.82B |
| CurrentDebtAndCapitalLeaseObligation | 5.80B | 7.49B | 4.71B | 3.46B |
| CurrentCapitalLeaseObligation | 1.74B | 1.75B | 1.74B | 1.68B |
| CurrentDebt | 4.07B | 5.74B | 2.97B | 1.78B |
| OtherCurrentBorrowings | 4.07B | 3.62B | 2.77B | 1.78B |
| CommercialPaper | 0.00 | 2.12B | 200.00M | 0.00 |
| PayablesAndAccruedExpenses | 81.77B | 75.93B | 73.33B | 63.15B |
| CurrentAccruedExpenses | 22.39B | 20.81B | 23.52B | 18.75B |
| Payables | 59.38B | 55.12B | 49.82B | 44.40B |
| OtherPayable | 41.74B | 39.23B | 34.92B | 29.57B |
| AccountsPayable | 17.64B | 15.89B | 14.90B | 14.84B |
| TotalAssets | 253.54B | 253.22B | 249.73B | 228.28B |
| TotalNonCurrentAssets | 178.82B | 184.57B | 181.87B | 162.64B |
| OtherNonCurrentAssets | 5.12B | 4.79B | 4.66B | 4.62B |
| DefinedPensionBenefit | 1.99B | 3.31B | 3.25B | 3.23B |
| InvestmentsAndAdvances | 32.67B | 28.93B | 23.02B | 21.10B |
| OtherInvestments | 4.57B | 3.80B | 3.25B | 2.54B |
| InvestmentinFinancialAssets | 28.10B | 25.13B | 19.77B | 18.55B |
| HeldToMaturitySecurities | 1.38B | 1.35B | 1.18B | 989.00M |
| AvailableForSaleSecurities | 26.72B | 23.78B | 18.58B | 17.56B |
| GoodwillAndOtherIntangibleAssets | 110.99B | 118.59B | 120.51B | 102.95B |
| OtherIntangibleAssets | 25.51B | 27.32B | 29.23B | 24.80B |
| Goodwill | 85.48B | 91.27B | 91.27B | 78.15B |
| NetPPE | 28.06B | 28.94B | 30.43B | 30.75B |
| AccumulatedDepreciation | -24.74B | -23.45B | -20.70B | -21.48B |
| GrossPPE | 52.80B | 52.38B | 51.13B | 52.23B |
| Leases | 6.81B | 6.72B | 6.51B | 6.24B |
| OtherProperties | 14.97B | 15.94B | 17.25B | 17.63B |
| MachineryFurnitureEquipment | 24.61B | 23.24B | 20.84B | 21.82B |
| BuildingsAndImprovements | 4.59B | 4.63B | 4.57B | 4.54B |
| LandAndImprovements | 1.81B | 1.85B | 1.96B | 2.00B |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 74.71B | 68.64B | 67.86B | 65.63B |
| OtherCurrentAssets | 5.09B | 3.08B | 3.15B | 2.64B |
| AssetsHeldForSaleCurrent | 0.00 | 908.00M | 0.00 | |
| Inventory | 19.25B | 18.11B | 18.02B | 19.09B |
| InventoriesAdjustmentsAllowances | -607.00M | -559.00M | ||
| OtherInventories | 18.63B | 19.65B | ||
| Receivables | 39.78B | 36.47B | 35.23B | 27.28B |
| OtherReceivables | 23.46B | 21.86B | 19.61B | 15.62B |
| AccountsReceivable | 16.32B | 14.61B | 15.62B | 11.66B |
| CashCashEquivalentsAndShortTermInvestments | 10.60B | 10.99B | 11.46B | 15.72B |
| OtherShortTermInvestments | 2.15B | 2.41B | 3.26B | 2.78B |
| CashAndCashEquivalents | 8.45B | 8.59B | 8.20B | 12.95B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 7.81B | 6.33B | 10.39B | 13.45B |
| RepurchaseOfCapitalStock | 0.00 | -3.02B | -2.01B | -3.50B |
| RepaymentOfDebt | -5.75B | -4.77B | -8.17B | -4.21B |
| IssuanceOfDebt | 3.97B | 9.83B | 16.10B | 0.00 |
| CapitalExpenditure | -2.83B | -2.78B | -3.03B | -2.73B |
| EndCashPosition | 8.71B | 8.88B | 8.53B | 13.30B |
| BeginningCashPosition | 8.88B | 8.53B | 13.30B | 12.69B |
| ChangesInCash | -172.00M | 359.00M | -4.78B | 614.00M |
| FinancingCashFlow | -4.94B | -1.14B | 2.68B | -10.52B |
| CashFlowFromContinuingFinancingActivities | -4.94B | -1.14B | 2.68B | -10.52B |
| NetOtherFinancingCharges | -158.00M | -159.00M | -382.00M | -449.00M |
| ProceedsFromStockOptionExercised | 394.00M | 361.00M | 277.00M | 551.00M |
| CashDividendsPaid | -3.40B | -3.37B | -3.13B | -2.91B |
| CommonStockDividendPaid | -3.40B | -3.37B | -3.13B | -2.91B |
| NetCommonStockIssuance | 0.00 | -3.02B | -2.01B | -3.50B |
| CommonStockPayments | 0.00 | -3.02B | -2.01B | -3.50B |
| NetIssuancePaymentsOfDebt | -1.78B | 5.06B | 7.93B | -4.21B |
| NetShortTermDebtIssuance | -2.12B | 1.92B | 200.00M | 0.00 |
| ShortTermDebtPayments | -2.12B | 0.00 | -5.00B | 0.00 |
| ShortTermDebtIssuance | 0.00 | 1.92B | 5.20B | 0.00 |
| NetLongTermDebtIssuance | 340.00M | 3.14B | 7.73B | -4.21B |
| LongTermDebtPayments | -3.63B | -4.77B | -3.17B | -4.21B |
| LongTermDebtIssuance | 3.97B | 7.91B | 10.90B | 0.00 |
| InvestingCashFlow | -5.87B | -7.61B | -20.89B | -5.05B |
| CashFlowFromContinuingInvestingActivities | -5.87B | -7.61B | -20.89B | -5.05B |
| NetOtherInvestingChanges | 26.00M | 101.00M | 68.00M | 85.00M |
| NetInvestmentPurchaseAndSale | -2.63B | -4.84B | -1.31B | -1.02B |
| SaleOfInvestment | 12.38B | 10.35B | 7.73B | 6.73B |
| PurchaseOfInvestment | -15.01B | -15.19B | -9.04B | -7.75B |
| NetBusinessPurchaseAndSale | -436.00M | -95.00M | -16.61B | -1.39B |
| SaleOfBusiness | 0.00 | 0.00 | 0.00 | |
| PurchaseOfBusiness | -436.00M | -95.00M | -16.61B | -1.39B |
| NetPPEPurchaseAndSale | -2.83B | -2.78B | -3.03B | -2.73B |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -2.83B | -2.78B | -3.03B | -2.73B |
| OperatingCashFlow | 10.64B | 9.11B | 13.43B | 16.18B |
| CashFlowFromContinuingOperatingActivities | 10.64B | 9.11B | 13.43B | 16.18B |
| ChangeInWorkingCapital | -1.47B | 109.00M | 15.00M | 6.82B |
| ChangeInOtherCurrentLiabilities | 2.01B | -3.54B | 1.54B | 6.46B |
| ChangeInOtherCurrentAssets | -2.59B | -38.00M | -510.00M | -491.00M |
| ChangeInPayablesAndAccruedExpense | 3.87B | 5.09B | 4.01B | 5.25B |
| ChangeInPayable | 3.87B | 5.09B | 4.01B | 5.25B |
| ChangeInAccountPayable | 3.85B | 2.33B | 3.62B | 4.26B |
| ChangeInInventory | -1.27B | -102.00M | 1.23B | -1.44B |
| ChangeInReceivables | -3.50B | -1.30B | -6.26B | -2.97B |
| ChangesInAccountReceivables | -3.50B | -1.30B | -6.26B | -2.97B |
| OtherNonCashItems | -336.00M | -502.00M | 264.00M | 332.00M |
| StockBasedCompensation | 535.00M | 540.00M | 588.00M | 447.00M |
| AssetImpairmentCharge | 5.72B | 840.00M | 152.00M | 0.00 |
| DeferredTax | 102.00M | -572.00M | -676.00M | -2.03B |
| DeferredIncomeTax | 102.00M | -572.00M | -676.00M | -2.03B |
| DepreciationAmortizationDepletion | 4.61B | 4.60B | 4.37B | 4.22B |
| DepreciationAndAmortization | 4.61B | 4.60B | 4.37B | 4.22B |
| OperatingGainsLosses | -247.00M | -491.00M | 349.00M | 2.06B |
| GainLossOnSaleOfBusiness | -247.00M | 0.00 | 0.00 | -475.00M |
| NetIncomeFromContinuingOperations | 1.73B | 4.59B | 8.37B | 4.33B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CVS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|